Troponin

OPTIMIZE Study Reports Lowest TLR Ever Achieved in an Investigational Device Exemption (IDE) Study With Svelte Medical System’s Bioresorbable Coated Drug-Eluting Coronary Stent

Saturday, October 17, 2020 - 5:00pm

The Svelte Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study.

Key Points: 
  • The Svelte Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study.
  • The high TLF reported in both OPTIMIZE treatment groups is driven by the 25% of study subjects assessed peri-procedurally with high-sensitivity-troponin.
  • We are deeply grateful to each and every one of the patients, investigative team members and support personnel contributing to the OPTIMIZE study.
  • Headquartered in New Providence, New Jersey, Svelte Medical Systems ( www.sveltemedical.com ) is a privately-held company engaged in the development of highly deliverable balloon expandable stents.

Cardiac Marker Analyzer Market Analysis 2011-2019 & 2020-2026 with the Impact of COVID-19

Tuesday, July 21, 2020 - 7:45pm

DUBLIN, July 21, 2020 /PRNewswire/ -- The "Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 21, 2020 /PRNewswire/ -- The "Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals" report has been added to ResearchAndMarkets.com's offering.
  • The global Cardiac Marker Analyzer market is predicted to reach US$ 4.5 Billion by 2026.
  • Cobas H232 POC system permits rapid and easy determination of cardiac blood markers such as Troponin T, NT-proBNP, D-dimer, CK-MB and myoglobin.
  • Cardiac Marker Analyzer - Mergers, Acquisitions, Distribution, Partnership and Licensing Agreements
    The Cardiac Marker Analyzer Covered in the report are as follows:

Cardiac Biomarkers - An Essential Tool in the Diagnosis and Management of Cardiovascular Diseases: Infinium Global Research

Wednesday, March 4, 2020 - 2:30pm

Over the last 50 years, cardiac biomarkers are being used for primary and secondary prevention, the diagnosis and management of acute myocardial infarction (AMI), and the diagnosis and risk stratification of heart failure (HF).

Key Points: 
  • Over the last 50 years, cardiac biomarkers are being used for primary and secondary prevention, the diagnosis and management of acute myocardial infarction (AMI), and the diagnosis and risk stratification of heart failure (HF).
  • Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/reports/sample-request/13335
    The use of a large number of cardiac biomarkers is becoming a routine in clinical diagnosis, differential diagnosis, risk stratification, and prognosis and guides the management of patients with suspected cardiovascular diseases.
  • In particular, cardiac troponins have become the cardiac markers of choice for patients with ACS and is generating the maximum revenue in the cardiac biomarkers market.
  • Geographically, North America is expected to dominate the market in terms of revenue in the global cardiac biomarkers market.

Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure

Tuesday, March 3, 2020 - 12:30pm

SOUTH SAN FRANCISCO, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data related to AMG 594 were presented at the Keystone Symposium Charting a New Course for Heart Failure: From Discovery to Data, in Keystone, Colo., characterizing its mechanism of action and effect to increase cardiac contractility.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data related to AMG 594 were presented at the Keystone Symposium Charting a New Course for Heart Failure: From Discovery to Data, in Keystone, Colo., characterizing its mechanism of action and effect to increase cardiac contractility.
  • AMG 594 is a novel mechanism cardiac troponin activator, discovered under a joint research program conducted between Amgen and Cytokinetics.
  • Several in vitro studies demonstrated that AMG 594 selectively increased the calcium sensitivity of the troponin complex in cardiac muscle.
  • In intact cardiac muscle fibers, AMG 594 increased calcium sensitivity and maximal isometric tension in a concentration-dependent manner.

Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date

Thursday, February 20, 2020 - 12:30pm

After review of this data, the independent expert concluded that he "does not see evidence of cardio-toxicity."

Key Points: 
  • After review of this data, the independent expert concluded that he "does not see evidence of cardio-toxicity."
  • The data made available included left ventricularejection fraction (LVEF) as determined by echocardiograms, ECHO strain imaging, and Troponin levels.
  • "ECHO strain imaging" is a method inechocardiography(medical ultrasound) for measuring regional or global deformation of the myocardium (heart muscle).
  • "We are pleased to receive this independent assessment which further validates the absence of cardiotoxicity in patients to date of Annamycin," stated Wally Klemp, Chairman and CEO of Moleculin.

Cytokinetics to Announce Fourth Quarter Results on March 3, 2020

Tuesday, February 18, 2020 - 9:00pm

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 3, 2020 at 4:00 PM Eastern Time.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 3, 2020 at 4:00 PM Eastern Time.
  • The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics website at www.cytokinetics.com .
  • An archived replay of the webcast will be available via Cytokinetics website until March 10, 2020.
  • Cytokinetics is collaborating with Astellas Pharma Inc. (Astellas) to develop reldesemtiv, a fast skeletal muscle troponin activator (FSTA).

Prevencio Announces Highly Accurate, AI-driven Blood Test with High Sensitivity (hs) Cardiac Troponin for the Diagnosis of Heart Disease

Tuesday, November 19, 2019 - 11:00am

Prevencio, Inc. today announces data confirming the high accuracy of its AI-driven, multiple-protein HART CADhs test, a biomarker clinical/proteomic panel inclusive of high sensitivity cardiac troponin for the diagnosis of obstructive Coronary Artery Disease (CAD), also known as heart disease.

Key Points: 
  • Prevencio, Inc. today announces data confirming the high accuracy of its AI-driven, multiple-protein HART CADhs test, a biomarker clinical/proteomic panel inclusive of high sensitivity cardiac troponin for the diagnosis of obstructive Coronary Artery Disease (CAD), also known as heart disease.
  • HART CADhs data from 1,152 patients were presented as Derivation and External Validation of a High Sensitivity Troponin Based Proteomic Model to Predict the Presence of Obstructive Coronary Artery Disease: Value in the Troponin Indeterminant Zone.
  • In this study, HART CADhs test was developed from 636 patient blood samples from MGH.
  • These patients need timely and accurate assessment, and we are hopeful this blood test will help both patients and clinicians.

U.S. FDA Clears Abbott's High Sensitivity Troponin-I Blood Test That Aids Doctors in Diagnosing Heart Attacks Faster and More Accurately

Wednesday, September 25, 2019 - 1:00pm

When people enter the emergency room with a suspected heart attack, doctors typically use a troponin blood test to help aid in their diagnosis.

Key Points: 
  • When people enter the emergency room with a suspected heart attack, doctors typically use a troponin blood test to help aid in their diagnosis.
  • Troponin-I proteins are released from the heart and can be found at elevated levels in the blood when the heart muscle has been damaged.
  • Abbott's High Sensitivity Troponin-I blood test measures very low levels of troponin, allowing doctors to evaluate heart attack in patients within two to four hours of admission.
  • "Our research using this high sensitivity assay has demonstrated it can provide doctors with the ability to detect or rule out a heart attack earlier.

Microfluidic Immunoassay Markets - Global Forecast to 2025

Thursday, September 19, 2019 - 1:45pm

DUBLIN, Sept. 19, 2019 /PRNewswire/ -- The "Microfluidic Immunoassay Market by Product Type (Lab-on-chip, POC Analyzers, Reagents and Assay), Technology, Application (Cardiac, Troponin, BNP) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 19, 2019 /PRNewswire/ -- The "Microfluidic Immunoassay Market by Product Type (Lab-on-chip, POC Analyzers, Reagents and Assay), Technology, Application (Cardiac, Troponin, BNP) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The non-LOC POC technologies segment is estimated to command the largest share of the global microfluidic immunoassay market in 2019.
  • On the basis of application, the cardiac biomarker detection segment is estimated to hold the largest share of the global microfluidic immunoassay market in 2019 and is poised to grow at the fastest CAGR during the forecast period.
  • North America commanded the largest share of the global microfluidic immunoassay market in 2019, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa.

$2 Bn Microfluidic Immunoassay Markets, 2025 by Product Type (Lab-on-chip, POC Analyzers, Reagents and Assay), Technology, Application (Cardiac, Troponin, BNP) - ResearchAndMarkets.com

Wednesday, September 18, 2019 - 11:27am

The "Microfluidic Immunoassay Market by Product Type (Lab-on-chip, POC Analyzers, Reagents and Assay), Technology, Application (Cardiac, Troponin, BNP) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microfluidic Immunoassay Market by Product Type (Lab-on-chip, POC Analyzers, Reagents and Assay), Technology, Application (Cardiac, Troponin, BNP) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • In addition, emerging economies and novel technologies such as paper-based microfluidics will further provide significant opportunities for the various stakeholders in this market.
  • The non-LOC POC technologies segment is estimated to command the largest share of the global microfluidic immunoassay market in 2019.
  • North America commanded the largest share of the global microfluidic immunoassay market in 2019, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa.